Balyasny Asset Management LLC Spectrum Pharmaceuticals Inc Transaction History

Balyasny Asset Management LLC

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	BUY	$0.7 - $1.4 $20,666 - $41,333	29,524 New	29,524 $23,000
Q1 2022 May 16, 2022	SELL	$0.63 - $1.59 $9,826 - $24,799	-15,597 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$1.27 - $2.42 $19,808 - $37,744	15,597 New	15,597 $20,000
Q4 2020 Feb 16, 2021	SELL	$3.38 - $5.14 $115,771 - $176,055	-34,252 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$2.99 - $4.9 $102,413 - $167,834	34,252 New	34,252 $140,000
Q3 2019 Nov 14, 2019	SELL	$7.03 - $9.7 $742,058 - $1.02 Million	-105,556 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$7.36 - $11.26 $396,277 - $606,260	53,842 Added 104.11%	105,556 $909,000
Q1 2019 May 15, 2019	SELL	$9.08 - $11.84 $2.34 Million - $3.05 Million	-257,783 Reduced 83.29%	51,714 $553,000
Q4 2018 Feb 14, 2019	SELL	$6.39 - $16.99 $163,143 - $433,771	-25,531 Reduced 7.62%	309,497 $2.71 Million
Q2 2018 Aug 14, 2018	SELL	$14.31 - $21.75 $692,532 - $1.05 Million	-48,395 Reduced 12.62%	335,028 $7.02 Million
Q1 2018 May 15, 2018	SELL	$16.09 - $23.07 $2.86 Million - $4.09 Million	-177,495 Reduced 31.64%	383,423 $6.17 Million
Q4 2017 Feb 14, 2018	BUY	$13.36 - $20.73 $7.49 Million - $11.6 Million	560,918	560,918 $10.6 Million

115K

Ticker SPPI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 188,164,000
Description
Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology and hematology drug products. The company's products under development include Eflapegrastim, a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia; Poziotinib, a novel irreversible tyrosine kinase inhibitor ...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.